

Global Antihemophilic Factor (Recombinant) Market Research Report 2023

<https://marketpublishers.com/r/G2C0D010AB97EN.html>

Date: December 2023

Pages: 88

Price: US\$ 2,900.00 (Single User License)

ID: G2C0D010AB97EN

Abstracts

Antihemophilic factor is a naturally occurring protein in the blood that helps blood to clot.

According to QYResearch's new survey, global Antihemophilic Factor (Recombinant) market is projected to reach US\$ 2994.2 million in 2029, increasing from US\$ 2152 million in 2022, with the CAGR of 4.8% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Antihemophilic Factor (Recombinant) market research.

The market for recombinant antihemophilic factor has witnessed significant growth in recent years. This can be attributed to several factors, including the increasing prevalence of hemophilia, advancements in recombinant DNA technology, and improved access to healthcare services. Hemophilia is a genetic bleeding disorder that requires lifelong treatment with antihemophilic factors, such as factor VIII or factor IX. Recombinant antihemophilic factor, produced using recombinant DNA technology, offers advantages over plasma-derived products, including enhanced safety, reduced risk of infection transmission, and increased supply stability.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Antihemophilic Factor (Recombinant) market with multiple angles, which provides sufficient supports to readers' strategy and decision making.

By Company

Takeda

Bayer

CSL

Pfizer

Biogen

Octapharma

Novo Nordisk

Sanofi

Sobi

Segment by Type

200IU

250IU

Segment by Application

Hospital

Clinic

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

The Antihemophilic Factor (Recombinant) report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)

Chapter 2: Global market size, regional market size. Market Opportunities and Challenges

Chapter 3: Companies' Competition Patterns

Chapter 4: Product Type Analysis

Chapter 5: Product Application Analysis

Chapter 6 to 10: Country Level Value Analysis

Chapter 11: Companies' Outline

Chapter 12: Market Conclusions

Chapter 13: Research Methodology and Data Source

Contents

1 REPORT OVERVIEW

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Antihemophilic Factor (Recombinant) Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 200IU

1.2.3 250IU

1.3 Market by Application

1.3.1 Global Antihemophilic Factor (Recombinant) Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hospital

1.3.3 Clinic

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 GLOBAL GROWTH TRENDS

2.1 Global Antihemophilic Factor (Recombinant) Market Perspective (2018-2029)

2.2 Antihemophilic Factor (Recombinant) Growth Trends by Region

2.2.1 Global Antihemophilic Factor (Recombinant) Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Antihemophilic Factor (Recombinant) Historic Market Size by Region (2018-2023)

2.2.3 Antihemophilic Factor (Recombinant) Forecasted Market Size by Region (2024-2029)

2.3 Antihemophilic Factor (Recombinant) Market Dynamics

2.3.1 Antihemophilic Factor (Recombinant) Industry Trends

2.3.2 Antihemophilic Factor (Recombinant) Market Drivers

2.3.3 Antihemophilic Factor (Recombinant) Market Challenges

2.3.4 Antihemophilic Factor (Recombinant) Market Restraints

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Antihemophilic Factor (Recombinant) Players by Revenue

3.1.1 Global Top Antihemophilic Factor (Recombinant) Players by Revenue

(2018-2023)

3.1.2 Global Antihemophilic Factor (Recombinant) Revenue Market Share by Players (2018-2023)

3.2 Global Antihemophilic Factor (Recombinant) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Antihemophilic Factor (Recombinant) Revenue

3.4 Global Antihemophilic Factor (Recombinant) Market Concentration Ratio

3.4.1 Global Antihemophilic Factor (Recombinant) Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Antihemophilic Factor (Recombinant) Revenue in 2022

3.5 Antihemophilic Factor (Recombinant) Key Players Head office and Area Served

3.6 Key Players Antihemophilic Factor (Recombinant) Product Solution and Service

3.7 Date of Enter into Antihemophilic Factor (Recombinant) Market

3.8 Mergers & Acquisitions, Expansion Plans

4 ANTIHEMOPHILIC FACTOR (RECOMBINANT) BREAKDOWN DATA BY TYPE

4.1 Global Antihemophilic Factor (Recombinant) Historic Market Size by Type (2018-2023)

4.2 Global Antihemophilic Factor (Recombinant) Forecasted Market Size by Type (2024-2029)

5 ANTIHEMOPHILIC FACTOR (RECOMBINANT) BREAKDOWN DATA BY APPLICATION

5.1 Global Antihemophilic Factor (Recombinant) Historic Market Size by Application (2018-2023)

5.2 Global Antihemophilic Factor (Recombinant) Forecasted Market Size by Application (2024-2029)

6 NORTH AMERICA

6.1 North America Antihemophilic Factor (Recombinant) Market Size (2018-2029)

6.2 North America Antihemophilic Factor (Recombinant) Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Antihemophilic Factor (Recombinant) Market Size by Country (2018-2023)

6.4 North America Antihemophilic Factor (Recombinant) Market Size by Country

(2024-2029)

6.5 United States

6.6 Canada

7 EUROPE

7.1 Europe Antihemophilic Factor (Recombinant) Market Size (2018-2029)

7.2 Europe Antihemophilic Factor (Recombinant) Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Antihemophilic Factor (Recombinant) Market Size by Country (2018-2023)

7.4 Europe Antihemophilic Factor (Recombinant) Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 ASIA-PACIFIC

8.1 Asia-Pacific Antihemophilic Factor (Recombinant) Market Size (2018-2029)

8.2 Asia-Pacific Antihemophilic Factor (Recombinant) Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Region (2018-2023)

8.4 Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 LATIN AMERICA

9.1 Latin America Antihemophilic Factor (Recombinant) Market Size (2018-2029)

9.2 Latin America Antihemophilic Factor (Recombinant) Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Antihemophilic Factor (Recombinant) Market Size by Country (2018-2023)

9.4 Latin America Antihemophilic Factor (Recombinant) Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Antihemophilic Factor (Recombinant) Market Size (2018-2029)

10.2 Middle East & Africa Antihemophilic Factor (Recombinant) Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Country (2018-2023)

10.4 Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 KEY PLAYERS PROFILES

11.1 Takeda

11.1.1 Takeda Company Detail

11.1.2 Takeda Business Overview

11.1.3 Takeda Antihemophilic Factor (Recombinant) Introduction

11.1.4 Takeda Revenue in Antihemophilic Factor (Recombinant) Business (2018-2023)

11.1.5 Takeda Recent Development

11.2 Bayer

11.2.1 Bayer Company Detail

11.2.2 Bayer Business Overview

11.2.3 Bayer Antihemophilic Factor (Recombinant) Introduction

11.2.4 Bayer Revenue in Antihemophilic Factor (Recombinant) Business (2018-2023)

11.2.5 Bayer Recent Development

11.3 CSL

11.3.1 CSL Company Detail

11.3.2 CSL Business Overview

- 11.3.3 CSL Antihemophilic Factor (Recombinant) Introduction
- 11.3.4 CSL Revenue in Antihemophilic Factor (Recombinant) Business (2018-2023)
- 11.3.5 CSL Recent Development
- 11.4 Pfizer
 - 11.4.1 Pfizer Company Detail
 - 11.4.2 Pfizer Business Overview
 - 11.4.3 Pfizer Antihemophilic Factor (Recombinant) Introduction
 - 11.4.4 Pfizer Revenue in Antihemophilic Factor (Recombinant) Business (2018-2023)
 - 11.4.5 Pfizer Recent Development
- 11.5 Biogen
 - 11.5.1 Biogen Company Detail
 - 11.5.2 Biogen Business Overview
 - 11.5.3 Biogen Antihemophilic Factor (Recombinant) Introduction
 - 11.5.4 Biogen Revenue in Antihemophilic Factor (Recombinant) Business (2018-2023)
 - 11.5.5 Biogen Recent Development
- 11.6 Octapharma
 - 11.6.1 Octapharma Company Detail
 - 11.6.2 Octapharma Business Overview
 - 11.6.3 Octapharma Antihemophilic Factor (Recombinant) Introduction
 - 11.6.4 Octapharma Revenue in Antihemophilic Factor (Recombinant) Business (2018-2023)
 - 11.6.5 Octapharma Recent Development
- 11.7 Novo Nordisk
 - 11.7.1 Novo Nordisk Company Detail
 - 11.7.2 Novo Nordisk Business Overview
 - 11.7.3 Novo Nordisk Antihemophilic Factor (Recombinant) Introduction
 - 11.7.4 Novo Nordisk Revenue in Antihemophilic Factor (Recombinant) Business (2018-2023)
 - 11.7.5 Novo Nordisk Recent Development
- 11.8 Sanofi
 - 11.8.1 Sanofi Company Detail
 - 11.8.2 Sanofi Business Overview
 - 11.8.3 Sanofi Antihemophilic Factor (Recombinant) Introduction
 - 11.8.4 Sanofi Revenue in Antihemophilic Factor (Recombinant) Business (2018-2023)
 - 11.8.5 Sanofi Recent Development
- 11.9 Sobi
 - 11.9.1 Sobi Company Detail
 - 11.9.2 Sobi Business Overview
 - 11.9.3 Sobi Antihemophilic Factor (Recombinant) Introduction

- 11.9.4 Sobi Revenue in Antihemophilic Factor (Recombinant) Business (2018-2023)
- 11.9.5 Sobi Recent Development

12 ANALYST'S VIEWPOINTS/CONCLUSIONS

13 APPENDIX

- 13.1 Research Methodology
 - 13.1.1 Methodology/Research Approach
 - 13.1.2 Data Source
- 13.2 Disclaimer
- 13.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Global Antihemophilic Factor (Recombinant) Market Size Growth Rate by Type (US\$ Million): 2018 VS 2022 VS 2029

Table 2. Key Players of 200IU

Table 3. Key Players of 250IU

Table 4. Global Antihemophilic Factor (Recombinant) Market Size Growth by Application (US\$ Million): 2018 VS 2022 VS 2029

Table 5. Global Antihemophilic Factor (Recombinant) Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 6. Global Antihemophilic Factor (Recombinant) Market Size by Region (2018-2023) & (US\$ Million)

Table 7. Global Antihemophilic Factor (Recombinant) Market Share by Region (2018-2023)

Table 8. Global Antihemophilic Factor (Recombinant) Forecasted Market Size by Region (2024-2029) & (US\$ Million)

Table 9. Global Antihemophilic Factor (Recombinant) Market Share by Region (2024-2029)

Table 10. Antihemophilic Factor (Recombinant) Market Trends

Table 11. Antihemophilic Factor (Recombinant) Market Drivers

Table 12. Antihemophilic Factor (Recombinant) Market Challenges

Table 13. Antihemophilic Factor (Recombinant) Market Restraints

Table 14. Global Antihemophilic Factor (Recombinant) Revenue by Players (2018-2023) & (US\$ Million)

Table 15. Global Antihemophilic Factor (Recombinant) Market Share by Players (2018-2023)

Table 16. Global Top Antihemophilic Factor (Recombinant) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antihemophilic Factor (Recombinant) as of 2022)

Table 17. Ranking of Global Top Antihemophilic Factor (Recombinant) Companies by Revenue (US\$ Million) in 2022

Table 18. Global 5 Largest Players Market Share by Antihemophilic Factor (Recombinant) Revenue (CR5 and HHI) & (2018-2023)

Table 19. Key Players Headquarters and Area Served

Table 20. Key Players Antihemophilic Factor (Recombinant) Product Solution and Service

Table 21. Date of Enter into Antihemophilic Factor (Recombinant) Market

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Antihemophilic Factor (Recombinant) Market Size by Type (2018-2023) & (US\$ Million)

Table 24. Global Antihemophilic Factor (Recombinant) Revenue Market Share by Type (2018-2023)

Table 25. Global Antihemophilic Factor (Recombinant) Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 26. Global Antihemophilic Factor (Recombinant) Revenue Market Share by Type (2024-2029)

Table 27. Global Antihemophilic Factor (Recombinant) Market Size by Application (2018-2023) & (US\$ Million)

Table 28. Global Antihemophilic Factor (Recombinant) Revenue Market Share by Application (2018-2023)

Table 29. Global Antihemophilic Factor (Recombinant) Forecasted Market Size by Application (2024-2029) & (US\$ Million)

Table 30. Global Antihemophilic Factor (Recombinant) Revenue Market Share by Application (2024-2029)

Table 31. North America Antihemophilic Factor (Recombinant) Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 32. North America Antihemophilic Factor (Recombinant) Market Size by Country (2018-2023) & (US\$ Million)

Table 33. North America Antihemophilic Factor (Recombinant) Market Size by Country (2024-2029) & (US\$ Million)

Table 34. Europe Antihemophilic Factor (Recombinant) Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 35. Europe Antihemophilic Factor (Recombinant) Market Size by Country (2018-2023) & (US\$ Million)

Table 36. Europe Antihemophilic Factor (Recombinant) Market Size by Country (2024-2029) & (US\$ Million)

Table 37. Asia-Pacific Antihemophilic Factor (Recombinant) Market Size Growth Rate by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 38. Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Region (2018-2023) & (US\$ Million)

Table 39. Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Region (2024-2029) & (US\$ Million)

Table 40. Latin America Antihemophilic Factor (Recombinant) Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 41. Latin America Antihemophilic Factor (Recombinant) Market Size by Country (2018-2023) & (US\$ Million)

Table 42. Latin America Antihemophilic Factor (Recombinant) Market Size by Country (2024-2029) & (US\$ Million)

Table 43. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 44. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Country (2018-2023) & (US\$ Million)

Table 45. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Country (2024-2029) & (US\$ Million)

Table 46. Takeda Company Detail

Table 47. Takeda Business Overview

Table 48. Takeda Antihemophilic Factor (Recombinant) Product

Table 49. Takeda Revenue in Antihemophilic Factor (Recombinant) Business (2018-2023) & (US\$ Million)

Table 50. Takeda Recent Development

Table 51. Bayer Company Detail

Table 52. Bayer Business Overview

Table 53. Bayer Antihemophilic Factor (Recombinant) Product

Table 54. Bayer Revenue in Antihemophilic Factor (Recombinant) Business (2018-2023) & (US\$ Million)

Table 55. Bayer Recent Development

Table 56. CSL Company Detail

Table 57. CSL Business Overview

Table 58. CSL Antihemophilic Factor (Recombinant) Product

Table 59. CSL Revenue in Antihemophilic Factor (Recombinant) Business (2018-2023) & (US\$ Million)

Table 60. CSL Recent Development

Table 61. Pfizer Company Detail

Table 62. Pfizer Business Overview

Table 63. Pfizer Antihemophilic Factor (Recombinant) Product

Table 64. Pfizer Revenue in Antihemophilic Factor (Recombinant) Business (2018-2023) & (US\$ Million)

Table 65. Pfizer Recent Development

Table 66. Biogen Company Detail

Table 67. Biogen Business Overview

Table 68. Biogen Antihemophilic Factor (Recombinant) Product

Table 69. Biogen Revenue in Antihemophilic Factor (Recombinant) Business (2018-2023) & (US\$ Million)

Table 70. Biogen Recent Development

Table 71. Octapharma Company Detail

Table 72. Octapharma Business Overview

Table 73. Octapharma Antihemophilic Factor (Recombinant) Product

Table 74. Octapharma Revenue in Antihemophilic Factor (Recombinant) Business (2018-2023) & (US\$ Million)

Table 75. Octapharma Recent Development

Table 76. Novo Nordisk Company Detail

Table 77. Novo Nordisk Business Overview

Table 78. Novo Nordisk Antihemophilic Factor (Recombinant) Product

Table 79. Novo Nordisk Revenue in Antihemophilic Factor (Recombinant) Business (2018-2023) & (US\$ Million)

Table 80. Novo Nordisk Recent Development

Table 81. Sanofi Company Detail

Table 82. Sanofi Business Overview

Table 83. Sanofi Antihemophilic Factor (Recombinant) Product

Table 84. Sanofi Revenue in Antihemophilic Factor (Recombinant) Business (2018-2023) & (US\$ Million)

Table 85. Sanofi Recent Development

Table 86. Sobi Company Detail

Table 87. Sobi Business Overview

Table 88. Sobi Antihemophilic Factor (Recombinant) Product

Table 89. Sobi Revenue in Antihemophilic Factor (Recombinant) Business (2018-2023) & (US\$ Million)

Table 90. Sobi Recent Development

Table 91. Research Programs/Design for This Report

Table 92. Key Data Information from Secondary Sources

Table 93. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Antihemophilic Factor (Recombinant) Market Size Comparison by Type (2023-2029) & (US\$ Million)

Figure 2. Global Antihemophilic Factor (Recombinant) Market Share by Type: 2022 VS 2029

Figure 3. 200IU Features

Figure 4. 250IU Features

Figure 5. Global Antihemophilic Factor (Recombinant) Market Size Comparison by Application (2023-2029) & (US\$ Million)

Figure 6. Global Antihemophilic Factor (Recombinant) Market Share by Application: 2022 VS 2029

Figure 7. Hospital Case Studies

Figure 8. Clinic Case Studies

Figure 9. Antihemophilic Factor (Recombinant) Report Years Considered

Figure 10. Global Antihemophilic Factor (Recombinant) Market Size (US\$ Million), Year-over-Year: 2018-2029

Figure 11. Global Antihemophilic Factor (Recombinant) Market Size, (US\$ Million), 2018 VS 2022 VS 2029

Figure 12. Global Antihemophilic Factor (Recombinant) Market Share by Region: 2022 VS 2029

Figure 13. Global Antihemophilic Factor (Recombinant) Market Share by Players in 2022

Figure 14. Global Top Antihemophilic Factor (Recombinant) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antihemophilic Factor (Recombinant) as of 2022)

Figure 15. The Top 10 and 5 Players Market Share by Antihemophilic Factor (Recombinant) Revenue in 2022

Figure 16. North America Antihemophilic Factor (Recombinant) Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 17. North America Antihemophilic Factor (Recombinant) Market Share by Country (2018-2029)

Figure 18. United States Antihemophilic Factor (Recombinant) Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 19. Canada Antihemophilic Factor (Recombinant) Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 20. Europe Antihemophilic Factor (Recombinant) Market Size YoY Growth

(2018-2029) & (US\$ Million)

Figure 21. Europe Antihemophilic Factor (Recombinant) Market Share by Country (2018-2029)

Figure 22. Germany Antihemophilic Factor (Recombinant) Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 23. France Antihemophilic Factor (Recombinant) Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 24. U.K. Antihemophilic Factor (Recombinant) Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 25. Italy Antihemophilic Factor (Recombinant) Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 26. Russia Antihemophilic Factor (Recombinant) Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 27. Nordic Countries Antihemophilic Factor (Recombinant) Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 28. Asia-Pacific Antihemophilic Factor (Recombinant) Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 29. Asia-Pacific Antihemophilic Factor (Recombinant) Market Share by Region (2018-2029)

Figure 30. China Antihemophilic Factor (Recombinant) Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 31. Japan Antihemophilic Factor (Recombinant) Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 32. South Korea Antihemophilic Factor (Recombinant) Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 33. Southeast Asia Antihemophilic Factor (Recombinant) Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 34. India Antihemophilic Factor (Recombinant) Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 35. Australia Antihemophilic Factor (Recombinant) Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 36. Latin America Antihemophilic Factor (Recombinant) Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 37. Latin America Antihemophilic Factor (Recombinant) Market Share by Country (2018-2029)

Figure 38. Mexico Antihemophilic Factor (Recombinant) Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 39. Brazil Antihemophilic Factor (Recombinant) Market Size YoY Growth (2018-2029) & (US\$ Million)

- Figure 40. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 41. Middle East & Africa Antihemophilic Factor (Recombinant) Market Share by Country (2018-2029)
- Figure 42. Turkey Antihemophilic Factor (Recombinant) Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 43. Saudi Arabia Antihemophilic Factor (Recombinant) Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 44. Takeda Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2018-2023)
- Figure 45. Bayer Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2018-2023)
- Figure 46. CSL Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2018-2023)
- Figure 47. Pfizer Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2018-2023)
- Figure 48. Biogen Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2018-2023)
- Figure 49. Octapharma Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2018-2023)
- Figure 50. Novo Nordisk Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2018-2023)
- Figure 51. Sanofi Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2018-2023)
- Figure 52. Sobi Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2018-2023)
- Figure 53. Bottom-up and Top-down Approaches for This Report
- Figure 54. Data Triangulation
- Figure 55. Key Executives Interviewed

I would like to order

Product name: Global Antihemophilic Factor (Recombinant) Market Research Report 2023

Product link: <https://marketpublishers.com/r/G2C0D010AB97EN.html>

Price: US\$ 2,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G2C0D010AB97EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970